A Pharmacodynamic Simulation to Assess Tigecycline Efficacy for Hospital-Acquired Pneumonia Compared with Other Common Intravenous Antibiotics

References

• Zhanel CC, Homenuik K, Nichol K, et al. Glycylcyclines: a comparative review with the tetracyclines. Drugs 2004; 64 (1): 63–88.
   PubMed Web of Science ®Google Scholar
• Pachon-Ibanez ME, Jimenez-Mejias ME, Pichardo C, Llanos AC, Pachon J. Activity of tigecycline (GAR-936) against Acinetobacter baumannii strains, including those resistant to imipenem. Antimicrob Agents Chemother 2004; 48 (11): 4479–4481.
   PubMed Web of Science ®Google Scholar
• Waites KB, Duffy LB, Dowzicky MJ. Antimicrobial sus-ceptibility among pathogens collected from hospitalized patients in the United States and in vivo activity of tigecycline, a new glycylcycline antimicrobial. Antimicrob Agents Chemother 2006; 50 (10): 3479–3484.
   PubMed Web of Science ®Google Scholar
• Dukart G, Cooper CA, Ellis-Grosse EJ. A phase 3 study comparing tigecycline and levofloxacin in patients with com-munity-acquired pneumonia [abstract 171]. In: Final Program and Abstracts of the 44th Annual Meeting of IDSA. Infectious Diseases Society of America, Alexandria, VA, 2006; 75.
   Google Scholar
• National Institutes of Health. Clinical Trial Registry. Available online at http://www.clinicaltrials.gov. Accessed November 7, 2006
   Google Scholar
• Conte JE, Golden JA, Grace Kelly M, Zurlinden E. Steady-state serum and intrapulmonary pharmacokinetics and pharmacodynamics of tigecycline. Int J Antimicrob Agents 2005; 25 (6): 523–529.
   PubMed Web of Science ®Google Scholar
• Saner FH, Heuer M, Rath P, et al. Successful salvage therapy with tigecycline after linezolid failure in a liver trans-plant recipient with MRSA pneumonia. Liver Transplant 2006; 12 (11): 1689–1692.
   PubMed Web of Science ®Google Scholar
• Craig WA. Pharmacokinetic/pharmacodynamic parame-ters: rationale for antibacterial dosing of mice and men. Clin Infect Dis 1998; 26 (1): 1–12.
   PubMed Web of Science ®Google Scholar
• Bradley JS, Dudley MN, Drusano GL. Predicting efficacy of anti-infectives with pharmacodynamics and Monte Carlo simulation. Pediatr Infect Dis J 2003; 22 (11): 982–992.
   PubMed Web of Science ®Google Scholar
• Sun HK, Kuti JL, Nicolau DP. Pharmacodynamics of antimicrobials for the empirical treatment of nosocomial pneu-monia: a report from the OPTAMA program. Crit Care Med 2005; 33 (10): 2222–2227.
   PubMed Web of Science ®Google Scholar
• Deryke CA, Kuti JL, Nicolau DP. Pharmacodynamic target attainment of 6 intravenous 13-lactams and 2 fluoro-quinolones against Pseudomonas aeruginosa, Acinetobacter baumannii, Escherichia coli, and Klebsiella species collected from U.S. intensive care units during 2004. Pharmacotherapy 2007; 27 (3): 333-342.
   Google Scholar
• Van Wart SA, Owen JS, Ludwig EA, Meagher AK, Korth-Bradley JM, Cirincione BB. Population pharmacokinet-ics of tigecycline in patients with complicated intra-abdominal or skin and skin structure infections. Antimicrob Agents Chemother 2006; 50 (11): 3701–3707.
   PubMed Web of Science ®Google Scholar
• Rebuck JA, Fish DN, Abraham E. Pharmacokinetics of intravenous and oral levofloxacin in critically ill adults in a medical intensive care unit. Pharmacotherapy 2002; 22 (10): 1216–1225.
   PubMed Web of Science ®Google Scholar
• Lodise TP, Lomaestro B, Rodvold KA, Danziger LH, Drusano GL. Pharmacodynamic profiling of piperacillin in the presence of tazobactam in patients through the use of popula-tion pharmacokinetic models and Monte Carlo simulation. Antimicrob Agents Chemother 2004; 48 (12): 4718–4724.
   PubMed Web of Science ®Google Scholar
• Young RJ, Lipman J, Gin T, Gomersall CD, Joynt GM, Oh TE. Intermittent bolus dosing of ceftazidime in critically ill patients. J Antimicrob Chemother 1997; 40 (2): 269–273.
   PubMed Web of Science ®Google Scholar
• Drusano GL, Plaisance KI, Forrest A, et al. Steady-state pharmacokinetics of imipenem in febrile neutropenic cancer patients. Antimicrob Agents Chemother 1987; 31 (9): 1420–1422.
   PubMed Web of Science ®Google Scholar
• Meagher AK, Passarell JA, Cirincione BB, et al. Exposure-response analyses of tigecycline efficacy in patients with complicated skin and skin-structure infections. Antimicrob Agents Chemother 2007; 51 (6): 1939–1945.
   PubMed Web of Science ®Google Scholar
• Passarell JA, Meagher AK, Liolios K, et al. Exposure-response analysis of tigecycline efficacy in patients with com-plicated intra-abdominal infections. Antimicrob Agents Chemother. 2008; 52 (1): 204–210.
   PubMed Web of Science ®Google Scholar
• Hoban DJ, Biendenbach DJ, Mutnick AH, Jones RN. Pathogen occurrence and susceptibility patterns associated with pneumonia in hospitalized patients in North America: results of the SENTRY Antimicrobial Surveillance Study (2000). Diagn Microbiol Infect Dis 2003; 45 (4): 279–285.
   PubMed Web of Science ®Google Scholar
• Drusano GL, Preston SL, Hardalo C, et al. Use of pre-clinical data for selection of a Phase II/III dose for evernimicin and identification of a preclinical breakpoint. Antimicrob Agents Chemother 2001; 45 (1): 13–22.
   PubMed Web of Science ®Google Scholar
• Wunderink RG, Rello J, Cammarata SK, Croos-Dabrera RV, Kollef MH. Analysis of two double blind studies of patients with methicillin-resistant Staphylococcus aureus nosocomial pneumonia. Chest 2003; 124 (5): 1789–1797.
   PubMed Web of Science ®Google Scholar
• Kuti J, Kiffer C, Mendes C, Nicolau D. Pharmaco-dynamic comparison of linezolid, teicoplanin and vancomycin against clinical isolates of Staphylococcus aureus and coagu-lase negative staphylococci collected from hospitals in Brazil. Clin Microbial Infect 2008; 14 (2): 116–123.
   PubMed Web of Science ®Google Scholar
• Ambrose PG, Grasela DM, Grasela TH, Passarell J, Mayer HB, Pierce PF. Pharmacodynamics of fluoroquinolones against Streptococcus pneumoniae in patients with communi-ty-acquired respiratory tract infections. Antimicrob Agents Chemother 2001; 45 (10): 2793–2797.
   PubMed Web of Science ®Google Scholar
• Drusano GL, Preston SL, Fowler C, Corrado M, Weisinger B, Kahn J. Relationship between fluoroquinolone area under the curve: minimum inhibitory concentration ratio and the probability of eradication of the infecting pathogen, in patients with nosocomial pneumonia. J Infect Dis 2004; 189 (9): 1590–1597.
   PubMed Web of Science ®Google Scholar
• Li C, Du X, Kuti JL, Nicolau DP. Clinical pharmacody-namics of meropenem in adult patients with lower respiratory tract infections. Antimicrob Agents Chemother 2007; 51 (5): 1725–1730.
   PubMed Web of Science ®Google Scholar
• Kuti JL, Nicolau DP. Making the most of surveillance studies: summary of the OPTAMA program. Diagn Microbiol Infect Dis 2005; 53 (4): 281–287.
   PubMed Web of Science ®Google Scholar
• Kuti JL, Ong C, Lo M, Melnick D, Soto N, Nicolau DP. Comparison of probability of target attainment calculated by Monte Carlo simulation with meropenem clinical and microbiological response for the treatment of complicated skin and skin structure infections. Int J Antimicrob Agents 2006; 28 (1): 62–68.
   PubMed Web of Science ®Google Scholar
• Rodvold KA, Gotfried MH, Cwik M, Korth-Bradley JM, Dukart G, Ellis-Grosse E. Serum, tissue, and body fluid con-centrations of tigecycline after a single 100 mg dose. J Antimicrob Chemother 2006; 58 (6): 1221–1229.
   PubMed Web of Science ®Google Scholar
• American Thoracic Society; Infectious Diseases Society of America. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associ-ated pneumonia. Am J Respir Crit Care Med 2005; 171 (4): 388–416.
   Google Scholar
• Van Ogtrop ML, Andes D, Stamstad TJ, et al. In vivo pharmacodynamic activities of two glycylcyclines (GAR-936 and WAY 152,288) against various Gram-positive and Gram-negative bacteria. Antimicrob Agents Chemother 2000; 44 (4): 943–949.
   PubMed Web of Science ®Google Scholar
• Ambrose PG, Bhavnani SM, Rubino CM, et al. Pharmacokinetics-pharmacodynamics of antimicrobial therapy: it's not just for mice anymore. Clin Infect Dis 2007; 44 (4): 79–86.
   PubMed Web of Science ®Google Scholar
• Moise PA, Forrest A, Bhavnani SM, Birmingham MC, Schentag JJ. Area under the inhibitory curve and a pneumo-nia scoring system for predicting outcomes of vancomycin therapy for respiratory infections by Staphylococcus aureus. Am J Health-Syst Pharm 2000; 57 (suppl 2): 84-89.
   Google Scholar